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Abstract The concentration of neuromelanin (NM) in substan-
tia nigra pars compacta (SNPC) has been measured in male and
female normal subjects at different ages in the range 1^97 years
old and in SNPC of parkinsonian patients. A very similar age
trend of NM concentration was found in both sexes. In the first
year of life NM was not detectable, between 10 and 20 years the
NM levels were 0.3^0.8 Wg/mg of SNPC, between 20 and 50
years were 0.8^2.3 Wg/mg SNPC and between 50 and 90 were
2.3^3.7 Wg/mg of SNPC. In parkinsonian subjects, the NM levels
were 1.2^1.5 Wg/mg of SNPC, which is less than 50% with
respect to the age-matched controls. These data demonstrate a
continuous NM accumulation in SNPC neurons during aging,
the presence of large amounts of NM in SNPC and severe
depletion of NM in Parkinson’s disease. ß 2002 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
Neuromelanin (NM) is an insoluble pigment found in neu-
rons of speci¢c brain regions of several animal species includ-
ing humans [1^6]. Neurons rich in NM are found especially in
the substantia nigra (SN) and locus coeruleus (LC) [5,7,8].
The structure and role of NM have been only partially char-
acterized [9^14] and are still a matter of investigation because
of the possible involvement in brain aging and Parkinson’s
disease (PD). In fact, this pigment ¢rst appears in humans
at 2^3 years of age and accumulates with aging [8]. NM is
possibly associated with the vulnerability of dopaminergic
neurons in the SN [15,16]. In PD the melanized neurons of
SN are more vulnerable than the non-melanized ones. How-
ever, such vulnerability is not correlated with the amount of
NM [17]. A recent study showed that NM synthesis is driven
by excess cytosolic catechols which are not accumulated in
synaptic vesicles [18]. A role of enzymatic activity of macro-
phage migration inhibitory factor was proposed in the NM
synthesis, since it oxidizes catecholamines to dihydroxyindole
derivatives and these are potential precursors of NM [19]. The
NM of SN shares some characteristics of melanins such as
redox activity and chelating ability for metals [2,20^23]. In
NM isolated from SN and LC, a signi¢cant amount of iron
was found [13]. Since iron can generate cytotoxic free radical,
NM, due to its strong chelating ability for iron and other
toxic metals (cadmium, mercury and manganese), could play
an important protective role in neurons [2,24,25]. In the SN
the presence of NM partially saturated with iron was indeed
shown [25]. NM speci¢cally adsorbs lipids at high molecular
weight and probably plays a role in the metabolism of brain
lipids [14]. There are di¡erent results about the loss of pig-
mented neurons in aging probably because of the di¡erent
methodologies in the counting of SN sections [26^30]. The
current methods for NM estimation are semiquantitative
[17,31] and are a¡ected by several limitations as detailed fur-
ther in Section 4. In a recent study the concentration of NM
in SN of a small group of normal male subjects was reported
[32]. Despite the interest in the NM role in PD, to date no
data have been reported about the variation of nigral NM
with aging in normal male and female subjects, nor its varia-
tion in PD patients. With the present work we describe a
precise and sensitive chemical method for NM determination
and report the age-related trend of NM accumulation in SN
pars compacta (SNPC) of normal subjects and parkinsonian
patients.
2. Materials and methods
2.1. Collection of samples
Samples of midbrain were removed from people who had died at
di¡erent ages without evidence of neurologic or psychiatric disorders.
These tissues were collected during autopsies carried out at the Insti-
tute of Forensic Medicine, University of Milan, Milan, Italy, and
Department of Pathology, IRCCS San Raphael Hospital, Milan,
Italy. Autopsies were carried out within 48 h of death. The SNPC
was carefully dissected and stored at 380‡C until assay. For NM
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determinations, 19 samples of SNPC from normal male subjects and
18 from normal females were employed in the age range from 1 to 97
years old. Further samples were used to isolate the NM to prepare the
calibration curves. The normal subjects included in this study at
pathological examination did not show macroscopic alterations of
neurologic and vascular type. At histological examination, no Lewy
bodies or other pathological markers were observed. Only in one
female subject, without story of PD symptoms, Lewy bodies and
consistent neuronal loss were observed. Samples of SNPC were also
taken from four male and three female PD patients with the same
procedure as above. Diagnosis of PD was established by clinical re-
cords and histologically con¢rmed by the presence of neuronal loss
and Lewy bodies in the SN.
This study was approved by the Ethical Committee of the C.N.R.
Institute of Biomedical Technologies (Milan, Italy) and was carried
out in agreement with the Policy of Italian National Research Coun-
cil.
2.2. Isolation of NM from SNPC for preparing calibration standards
Pooled SNPC samples were weighed and processed for NM isola-
tion as previously described [12^14]. The identity and purity of the
obtained NM sample was con¢rmed by the following determinations.
Elemental analysis (%): carbon = 58.80; hydrogen = 7.16; nitro-
gen = 6.51; sulfur = 2.56. The total amino acid content was 9.4%.
The electron paramagnetic spectrum showed typical g4 and g2 signals.
Purity was over 98%.
2.3. Procedure of NM determination
The SNPC of each subject was carefully ground in a plastic tube,
then a 10 mg aliquot of ground tissue was weighed into a 5 ml glass
tube. Then, 1.5 ml of pH 7.4 phosphate bu¡er (50 mM) was added,
the tube shaken, centrifuged at 9000Ug for 30 min and the super-
natant discarded. Washing with phosphate bu¡er was repeated one
more time. The pellet was incubated with shaking for 2 h at 37‡C with
1.5 ml of Tris bu¡er (50 mM, pH 7.4) solution containing sodium
dodecyl sulfate (5 mg/ml) and 0.2 mg/ml proteinase K (EC 3.4.21.14;
Sigma, St. Louis, MO, USA). The ¢ne suspension of pigment was
centrifuged at 9000Ug for 30 min. The pellet was washed with 1.5
ml of NaCl solution (9 mg/ml) and 1.5 ml of water, then centrifuged
with the above given conditions. The NM residue was dissolved in
1 ml of 1 M NaOH at 80‡C for 1 h. The obtained solution was
centrifuged and the supernatant transferred into a quartz cuvette,
and its absorbance at 350 nm was measured by spectrophotometer.
Calibrations curves were run by dissolving known amounts (1, 5, 10,
20 and 30 Wg) of NM in 1 ml of 1 M NaOH at 80‡C for 1 h. To this
purpose, NM isolated from SNPC as described above was suspended
in water (0.5 mg/ml), then diluted to a lower concentration to obtain a
suspension which was employed for the preparation of the calibration
curve. The values presented in this work are the average content of
NM from three to ¢ve determinations in the analyzed samples. The
NM content in SN tissue was stable for not less than 96 h after death
(data not shown).
Protein concentration was measured in each sample by using the
Lowry method [33].
2.4. Recovery of NM from brain tissue
In order to evaluate the recovery of NM in the analysis of SN
tissue, aliquots of white matter from normal human brain were em-
ployed, since this region is known not to contain NM. Standards of
NM prepared as described above were added to white matter samples
which were ground and processed for NM determination as described
above.
2.5. Statistical analysis
The data were analyzed using paired Student’s t-test and ANOVA.
Values are given as mean þ S.E.M.
3. Results
The parameters of the assay method here reported are given
in Table 1. It appears that this method is linear in the adopted
concentration range, and has good sensitivity, reproducibility
and recovery.
For both sexes there was a clear variation of NM concen-
trations according to the subjects age, with the levels steadily
increasing with senescence. In males (Fig. 1A), the youngest
subject aged 10 months, the concentration of NM was below
the method’s detection limit, i.e. less than 0.05 Wg/mg SNPC,
which is well in agreement with histological studies showing
the appearance of the ¢rst granules of NM at the age of 2^3
years. Levels of NM in teenagers were found to be between
0.5 and 1.0 Wg/mg SNPC. Then, an increase of NM concen-
tration occurs throughout all the rest of the life span until the
Table 1
Main parameters of the new method for NM determination
Linearity Interassay reproducibility (CV, %) Detection limit Recovery (%)
Y = 0.0053X+0.0083 R2 = 0.9896 4.96 (n = 4) 50 ng/mg tissue 83.2 þ 7.1 (n = 3)
Fig. 1. A: NM content (Wg/mg tissue) in SNPC of normal male sub-
jects (F) at di¡erent ages and four parkinsonian patients (E).
B: NM content (Wg/mg protein) in SNPC of the same normal sub-
jects. Values are given as mean þ S.E.M. of three to ¢ve determina-
tions for each subject.
FEBS 25650 9-1-02
L. Zecca et al./FEBS Letters 510 (2002) 216^220 217
latest phase of life when levels around 3.5 Wg/mg are present.
Individual variations occur over this increasing trend. A very
similar time course of NM concentration is observed in nor-
mal females (Fig. 2A) with an analogous trend as to age. One
outstanding exception was a female aged 69 whose NM value
of 1.61 Wg/mg was much lower than the average level at this
age. This subject died of a cardiovascular condition and had
no parkinsonian signs. However, the neuropathological ex-
amination revealed the presence of Lewy bodies and extensive
loss of melanized neurons in SNPC, thus showing a condition
of preclinical PD.
The four PD subjects in the male group had NM signi¢-
cantly lower concentrations than normal subjects (P6 0.05,
t-test) in the corresponding age interval that is 75^85. In the
female group the three PD subjects also had a signi¢cantly
lower concentration (P6 0.05, t-test) of NM than correspond-
ing normal subjects (age interval 75^85). In both male and
female groups the PD patients had a 50^60% average decrease
of NM concentration, which is in good agreement with that of
neuronal loss of pigmented neurons histologically observed.
The concentration of proteins found in the SNPC samples
was in the range 95^140 Wg/mg wet tissue.
NM concentrations, expressed as values in Wg/mg protein,
of the same normal male subjects and female subjects are
given in Figs. 1B and 2B, respectively. Due to the paucity
of SN tissue obtained from parkinsonian subjects, the protein
determination was not su⁄ciently accurate to calculate con-
centrations also as Wg/mg protein; therefore values for par-
kinsonian subjects are shown only as Wg/mg SN tissue.
Since normal male and female subjects had very similar
concentration of NM in the corresponding age ranges, all
values were pooled and the ¢tting analysis performed by using
several regression models. Among all tested models, the linear,
logistic and quadratic ones resulted to better ¢t to the exper-
imental data. By applying these approaches, and as shown in
Fig. 3, the relationship between NM concentration and age
was linear (Y = 0.040645X+0.0009231).
4. Discussion
To our knowledge this is the ¢rst report concerning the
absolute content of NM in the SN of normal male and female
subjects at di¡erent ages, and PD patients. The NM assay
here reported consists of a new, sensitive and speci¢c method
of quite acceptable reliability. Moreover, this method is sim-
ple, rapid and accurate and therefore suitable as a routine
assay of NM in normal and pathological SN, in addition to
the measurement of dopamine and other parameters.
Previous assessments of the NM content in SNPC were
based only on histological methods and indirect determina-
tions. Those studies reported qualitative [30] and semiquanti-
tative [19,31] evaluation of NM neuronal content by histolog-
ical methods employing stained and unstained sections of
SNPC. The semiquantitative evaluation of NM content in
stained and unstained sections [17,31] was performed using
as a reference standard a synthetic dopamine-derived melanin,
whose structure is quite di¡erent from that of authentic NM
of SN [13,14]. Another potential source of error in histological
studies is that the NM aggregates estimated within neurons
contain large amounts of lipids and peptides associated with
NM, as reported [14]. Furthermore, the use of a suspension of
synthetic melanin of unknown concentration poses an addi-
tional limitation resulting in an unreliable estimate of NM.
Histological studies [17,30,31] reported that lightly melanized
Fig. 2. A: NM content (Wg/mg tissue) in SNPC of normal female
subjects (b) at di¡erent ages, one subject with preclinical PD (R),
and three parkinsonian patients (a). B: NM content (Wg/mg pro-
tein) in SNPC of the same normal subjects and the subject with pre-
clinical PD (R). Values are given as mean þ S.E.M. of three to ¢ve
determinations for each subject.
Fig. 3. Regression analysis of the relationship between NM content
(Wg/mg tissue) and age, of male and female subjects at di¡erent
ages. The data from the two groups of subjects were pooled togeth-
er. Data best ¢t to a linear regression model.
FEBS 25650 9-1-02
L. Zecca et al./FEBS Letters 510 (2002) 216^220218
neurons are more vulnerable than heavily melanized ones in
PD.
Other studies [26,28,29] on age trend of the number of
pigmented neurons in SNPC reported either an age-dependent
loss [26] or no variations [27^29]. However, di¡erent counting
methods were employed in these studies. The absolute number
of pigmented neurons in SNPC of normal subjects seems to be
dependent on the ethnic group [28].
In the present work in both male and female subjects a
progressive accumulation of NM has been documented with
aging and the values are in the range 0^3.5 Wg/mg of SNPC.
The only exception was observed in one woman, aged 69, who
had very low NM concentration at the level found in subjects
aged less than 35 and she was found to be a case of preclinical
PD. The age trend of total NM concentration in SNPC re-
ported here is quite di¡erent from the age trend of the number
of melanized neurons in SNPC reported in previous studies
[26^29]. In fact, the previously mentioned studies described
the distribution of pigmented neurons in speci¢c layers of
SN. Our method measures the total NM content in SNPC
including the low amount of extraneuronal NM the magni-
tude of which should not signi¢cantly a¡ect the total amount
of neuronal NM.
In both male and female PD patients the percentage of
decrease of NM concentration is similar to that of neuronal
loss reported in neuropathological studies [26,27].
Previous studies showed a decreased level of pigmentation
in the surviving neurons in PD patients [17,31]. This could be
the result of a reduced NM synthesis, increased NM degrada-
tion, higher vulnerability of heavily pigmented neurons or a
combination thereof. Since pigmented neurons may have dif-
ferent NM content, so an evaluation of the neuronal content
of NM in the di¡erent cellular groups should be done in
future studies on normal subjects and PD patients, by using
the present method and neuronal counting on the same SNPC
samples.
Because of the documented ability of NM to bind toxins
such as redox active metals, cadmium, mercury, manganese,
pesticides, etc. [23,34^36], NM could play, in a ¢rst phase,
an e⁄cient protective role in neurons. Moreover, the NM
synthesis itself is a protective mechanism since it removes
the excess cytosolic catechols which are not accumulated in
synaptic vesicles [18]. However, when peroxidation processes
prevail, the NM may be degraded, consequently releasing
large amounts of toxins into the cytosol. If this is the case,
then NM alone may not be a factor in increasing neuronal
vulnerability but probably behaves as a sink collecting toxins
which in some conditions can be broken releasing its con-
tent.
NM appears to be a good marker of damage to the SNPC
in PD. As such, the development of NM in vivo imaging
techniques may o¡er diagnostic and disease staging measure-
ments matching the available tools used to monitor striatal
dopamine depletion and o¡ering the ¢rst direct approach to
recognize and quantify nigral damage. The concentration val-
ues of NM here described could be used for correlation with
in vivo images of SN in normal and PD subjects.
Further studies should expand the above observations in
other extrapiramidal disorders to asses speci¢city of NM de-
pletion and correlation with other established markers of ni-
grostriatal dysfunction.
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